A nurse caring for a client with decompensated heart failure understands that dobutamine will produce therapeutic outcomes by which mechanism?

Rationale: A. decreased heart rate: Dobutamine primarily acts as a beta-1 adrenergic agonist, which increases myocardial contractility and stroke volume. It may slightly increase heart rate, but decreasing heart rate is not its main therapeutic mechanism in decompensated heart failure. B. increased vascular resistance: Dobutamine generally has minimal alpha-adrenergic activity at therapeutic doses, so it does not significantly increase systemic vascular resistance. In fact, it may slightly decrease afterload, which helps improve cardiac output in heart failure. C. increased cardiac output: Dobutamine enhances myocardial contractility and stroke volume through beta-1 stimulation, leading to increased cardiac output. This effect reduces symptoms of decompensated heart failure, improves tissue perfusion, and supports end-organ function. D. decreased blood pressure: While dobutamine may lower vascular resistance slightly, its main therapeutic effect is not to decrease blood pressure. Any change in blood pressure is secondary to improved cardiac output rather than a primary mechanism of action.